Attached files
| file | filename |
|---|---|
| 8-K - 2ND QUARTER FINANCIALS - Gadsden Properties, Inc. | form8-k.htm |
EXHIBIT 99.1
|
Contacts:
|
LHA
Kim Sutton Golodetz
212-838-3777
Kgolodetz@lhai.com
Bruce Voss, 310-691-7100
Bvoss@lhai.com
|
PhotoMedex, Inc.
Dennis McGrath, Chief Financial Officer
215-619-3287
info@photomedex.com
|
|
|
@LHA IR PR
|
PHOTOMEDEX REPORTS SECOND QUARTER 2012 FINANCIAL RESULTS
Revenues increased 74% over the same period in 2011, consumer revenues increased 55%
MONTGOMERYVILLE, Pa. (August 8, 2012) – PhotoMedex, Inc. (NASDAQ and TASE: PHMD) today reported financial results for the three and six months ended June 30, 2012. Financial highlights of the 2012 second quarter include:
|
·
|
Revenues of $58.9 million, an increase of 74% compared with the prior-year second quarter and an increase of 17% sequentially
|
|
·
|
Consumer revenues of $50.5 million, an increase of 55% compared with the prior-year second quarter and an increase of 20% sequentially
|
|
·
|
Global retail and home shopping channel revenues of $9.8 million, an increase of 101% compared with the prior-year second quarter and an increase of 63% sequentially
|
|
·
|
Gross profit of $46.5 million, an increase of 65% compared with the second quarter of 2011 and an increase of 19% sequentially
|
|
·
|
Gross margin of 79.0% compared with 77.7% in the 2012 first quarter; prior-year second quarter gross margin of 83.2% does not include revenues from the pre-merged PhotoMedex
|
|
·
|
Income before taxes, litigation expenses and other one-time expenses of $9.0 million; net income of $4.2 million or $0.20 per diluted share
|
|
·
|
One-time expenses including for past litigation of $4.0 million or $0.19 per diluted share
|
|
·
|
Adjusted income of $12.2 million or $0.58 per diluted share
|
On December 13, 2011 Radiancy, Inc. became a majority owned subsidiary of PhotoMedex in a reverse merger. In accordance with generally accepted accounting principles (GAAP), Radiancy is deemed to be the financial acquirer for financial statement purposes and therefore the related consolidated statements of operations for the periods prior to December 31, 2011 do not include activity from the pre-merged PhotoMedex prior to the date of merger.
Reported Financial Results
Revenues for the second quarter of 2012 were $58.9 million, an increase of 74% over the same period last year. Included in this amount is $7.1 million in revenues from pre-merged PhotoMedex. This compares with revenues for the second quarter of 2011 of $33.8 million, which included no revenues from pre-merged PhotoMedex.
Net income for the second quarter of 2012 was $4.2 million or $0.20 per diluted per share, which included $1.5 million in stock-based compensation expense, $1.4 million in depreciation and amortization expenses, $3.8 million in expenses for past litigation and $0.2 million in other one-time charges. This compares with a net loss for the second quarter of 2011 of $10.0 million or $0.98 per share, which included $14.8 million in stock-based
compensation expense, $0.1 million in depreciation and amortization expenses, $0.1 million in expenses for past litigation and $12.4 million in merger-related expenses.
Revenues for the six months ended June 30, 2012 were $109.2 million, an increase of 59% over the same period last year. Included in this amount is $14.2 million in revenues from pre-merged PhotoMedex. This compares with revenues for the six months ended June 30, 2011 of $68.6 million, which included no revenues from pre-merged PhotoMedex.
Net income for the six months ended June 30, 2012 was $9.1 million or $0.45 per diluted per share, which included $3.3 million in stock-based compensation expense, $2.8 million in depreciation and amortization expenses, $5.6 million in expenses for past litigation and $0.7 million in other one-time charges. This compares with a net loss for the six months ended June 30, 2011 of $2.0 million or $0.19 per share, which included $14.8 million in stock-based compensation expense, $0.2 million in depreciation and amortization expenses, $0.8 million in expenses for past litigation and $12.4 million in merger-related expenses.
As of June 30, 2012, the Company had cash and cash equivalents of $52.9 million. On April 27, 2012, the Company raised $37.5 million in net proceeds from concurrent registered offerings of 3,023,432 shares of common stock. For the six months ended June 30, 2012, working capital increased by $51.0 million.
On a pro forma basis, had the merger been completed on January 1, 2011, revenues for the three months ended June 30, 2011 would have been $42.3 million, gross profit would have been $32.3 million and the net loss would have been $12.3 million.
Management expects revenues for the third quarter of 2012 to approximate second quarter levels.
Dr. Dolev Rafaeli, PhotoMedex CEO, commented, “Our second quarter financial performance was strong with revenues above our minimum expectations and continued growth in the consumer segment for another consecutive quarter. Gross margins in the physician recurring and professional equipment segments were much improved over the first quarter of this year, reflecting the consolidation of manufacturing to our facility in Carlsbad, California and our continuing effort to optimize our organization and leverage our global resources.
“Our consumer marketing programs continued to shine. We recently reported that sales of no!no! HairTM broke Home Shopping Network sales records in the U.S. at a 24-hour beauty event held over the Fourth of July holiday. Those products were shipped in the second quarter, including two new retro limited-edition devices, and were completely sold out during the event. We continued our geographic expansion by entering Korea and sold out within 45 minutes of launch. We are on track to add geographies in Europe by the end of the year.”
Dr. Rafaeli continued, “We believe XTRAC® for the treatment of psoriasis has significant growth potential and that effective marketing can spur demand. We see continued success with our pilot direct-to-consumer program via short-form television ads in select U.S. cities. We have now expanded the program to a pilot media campaign in Philadelphia with the goal of refining our message and developing standard operating procedures to promote and drive utilization. Psoriasis patients represent a large, under-served market and today are largely unaware of XTRAC® therapy. Importantly, patient satisfaction with the therapy is very high.”
“We also continue to be pleased with initial progress in developing a direct-to-consumer platform for our Neova® brand of skin rejuvenation products,” he said. “During the quarter these products were featured on the television show ‘The Doctors’ and we launched a consumer website at www.neova.com. We have also co-marketed Neova® products with no!no!® products and have high expectations for the growth of this line.”
A reconciliation of non-GAAP financial measures to GAAP financial measures, and a presentation of the most directly comparable GAAP financial measures are included below.
Non-GAAP Measures
To supplement PhotoMedex’s consolidated financial statements presented in accordance with GAAP, PhotoMedex provides certain non-GAAP measures of financial performance. These non-GAAP measures include non-GAAP adjusted income and non-GAAP adjusted income per share.
PhotoMedex’s reference to these non-GAAP measures should be considered in addition to results prepared under current accounting standards, but are not a substitute for, nor superior to, GAAP results. These non-GAAP measures are provided to enhance investors' overall understanding of PhotoMedex’s current financial performance and to provide further information for comparative purposes.
Specifically, the Company believes the non-GAAP measures provide useful information to both management and investors by isolating certain expenses, gains and losses that may not be indicative of the Company’s core operating results and business outlook. In addition, PhotoMedex believes non-GAAP measures enhance the comparability of results against prior periods. Reconciliation to the most directly comparable GAAP measure of all non-GAAP measures included in this press release is as follows:
(Unaudited)
|
Three Months Ended June 30,
|
Six Months ended June 30,
|
|||||||||||||||
|
(ooo's) except per share amounts
|
2012
|
2011 | * | 2012 | 2011 | * | ||||||||||
|
Net income (loss) as reported
|
$ | 4,213 | $ | (10,045 | ) | $ | 9,070 | $ | (1,960 | ) | ||||||
|
Adjustments:
|
||||||||||||||||
|
Stock-based compensation expense
|
1,535 | 14,786 | 3,288 | 14,836 | ||||||||||||
|
Depreciation and amortization expense
|
1,389 | 92 | 2,771 | 184 | ||||||||||||
|
Merger related expense
|
- | 12,364 | - | 12,364 | ||||||||||||
|
Investment banking and related fees
|
- | - | 400 | - | ||||||||||||
|
Completed litigation expense
|
3,801 | 118 | 5,595 | 798 | ||||||||||||
|
Severance and related integration costs
|
166 | - | 254 | - | ||||||||||||
|
Interest expense, net
|
219 | - | 408 | - | ||||||||||||
|
Income tax expense
|
866 | (6,202 | ) | 1,106 | (3,367 | ) | ||||||||||
|
Non-GAAP adjusted income
|
$ | 12,189 | $ | 11,113 | $ | 22,892 | $ | 22,855 | ||||||||
|
Common Shares outstanding at June 30, 2012
|
21,881 | 21,881 | 21,881 | 21,881 | ||||||||||||
|
Non-GAAP adjusted income per share
|
$ | 0.56 | $ | 0.51 | $ | 1.05 | $ | 1.04 | ||||||||
*As a result of purchase accounting rules, the operating results of the pre-merged PhotoMedex for the three-month and six-month period ended June 30, 2011 are not included in the consolidated statements of operations for the periods ended June 30, 2011.
Conference Call
PhotoMedex will hold a conference call to discuss the Company’s second quarter 2012 results and answer questions today, August 8, 2012 beginning at 4:30 p.m. Eastern time.
To participate in the conference call, dial U.S./toll free 888-455-2267, International/toll 719-325-2442 or Israel/toll free 180-925-8243 (and confirmation code # 5828425) approximately five to 10 minutes prior to the scheduled start time. If you are unable to participate, a digital replay of the call will be available from 7:30 p.m. ET Wednesday, August 8 until 7:30 p.m. ET Wednesday, August 22, 2012 by dialing U.S./toll free 888-203-1112 or International/toll 719-457-0820 and using confirmation code # 5828425.
The live broadcast of PhotoMedex, Inc.'s quarterly conference call will be available online by going to www.photomedex.com and clicking on the link to Investor Relations, and at www.streetevents.com. The online replay will be available shortly after the conclusion of the call at those sites.
About PhotoMedex
PhotoMedex is a global skin health company providing integrated disease management and aesthetic solutions to dermatologists, professional aestheticians and consumers. The company provides proprietary products and services that address skin diseases and conditions including psoriasis, vitiligo, acne, actinic keratosis (a precursor to certain types of skin cancer) and photo damage. Its experience in the physician market provides the platform to expand its skin health solutions to spa markets, as well as traditional retail, online and infomercial outlets for home-use products. As a result of its December 2011 merger with Radiancy Inc., PhotoMedex has added a range of home-use devices under the no!no!™ brand, for various indications including hair removal, acne treatment and skin rejuvenation. The company also offers a professional product line for acne clearance, skin tightening, psoriasis care and hair removal sold to physician clinics and spas.
SAFE HARBOR STATEMENT
Some portions of the conference call, particularly those describing PhotoMedex' strategies, operating expense reductions and business plans will contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including any statements of the plans, strategies and objectives of management for future operations; any statements regarding product development, product extensions, product integration or product marketing; any statements regarding continued compliance with government regulations, changing legislation or regulatory environments; any statements of expectation or belief and any statements of assumptions underlying any of the foregoing. In addition, there are risks and uncertainties related to successfully integrating the products and employees of the Company and Radiancy, as well as the ability to ensure continued regulatory compliance, performance and/or market growth. These risks, uncertainties and other factors, and the general risks associated with the businesses of the Company described in the reports and other documents filed with the SEC, could cause actual results to differ materially from those referred to, implied or expressed in the forward-looking statements. The Company cautions readers not to rely on these forward-looking statements. All forward-looking statements are based on information currently available to the Company and are qualified in their entirety by this cautionary statement. The Company anticipates that subsequent events and developments will cause its views to change. The information contained in this conference call speaks as of the date hereof and the Company has or undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
.
-- Financial Statements follow --
PHOTOMEDEX, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
|
Three Months Ended June 30,
|
Six Months Ended June 30,
|
|||||||||||||||
|
(ooo's) except per share amounts
|
2012
|
2011 | * | 2012 | 2011 | * | ||||||||||
|
Revenues
|
$ | 58,906 | $ | 33,847 | $ | 109,179 | $ | 68,588 | ||||||||
|
Cost of revenues
|
12,355 | 5,690 | 23,589 | 11,912 | ||||||||||||
|
Gross profit
|
46,551 | 28,157 | 85,590 | 56,676 | ||||||||||||
|
Operating expenses:
|
||||||||||||||||
|
Selling and marketing
|
31,068 | 15,390 | 56,903 | 30,037 | ||||||||||||
|
General and administrative
|
9,243 | 28,926 | 16,362 | 31,739 | ||||||||||||
|
Research and development and engineering
|
760 | 249 | 1,518 | 419 | ||||||||||||
| 41,071 | 44,565 | 74,783 | 62,195 | |||||||||||||
|
Operating income (loss)
|
5,480 | (16,408 | ) | 10,807 | (5,519 | ) | ||||||||||
|
Interest and other financing income (expense), net
|
(401 | ) | 161 | (631 | ) | 192 | ||||||||||
|
Income (loss) before taxes expense
|
5,079 | (16,247 | ) | 10,176 | (5,327 | ) | ||||||||||
|
Income tax expense (benefit)
|
866 | (6,202 | ) | 1,106 | (3,367 | ) | ||||||||||
|
Net income (loss) 1
|
$ | 4,213 | $ | (10,045 | ) | $ | 9,070 | $ | (1,960 | ) | ||||||
|
Net income (loss) per share:
|
||||||||||||||||
|
Basic
|
$ | 0.20 | $ | (0.98 | ) | $ | 0.47 | $ | (0.19 | ) | ||||||
|
Diluted
|
$ | 0.20 | $ | (0.98 | ) | $ | 0.45 | $ | (0.19 | ) | ||||||
|
Shares used in computing net income (loss) per share:
|
||||||||||||||||
|
Basic
|
20,547 | 10,256 | 19,455 | 10,256 | ||||||||||||
|
Diluted
|
21,035 | 10,256 | 19,942 | 10,256 | ||||||||||||
|
1 Includes: depreciation and amortization
|
1,389 | 92 | 2,771 | 184 | ||||||||||||
|
Share-based compensation expense
|
1,535 | 14,786 | 3,288 | 14,836 | ||||||||||||
*As a result of purchase accounting rules, the operating results of the pre-merged PhotoMedex for the three-month and six-month period ended June 30, 2011 are not included in the above consolidated statements of operations for the periods ended June 30, 2011.
|
PHOTOMEDEX, INC.
|
||||||||||||
|
CONSOLIDATED STATEMENTS OF REVENUES
|
||||||||||||
|
(UNADUDITED)
|
||||||||||||
|
For the Three Months Ended:
|
||||||||||||
|
June 30, 2012
|
March 31, 2012
|
June 30, 2011
|
||||||||||
|
Consumer:
|
||||||||||||
|
Direct
|
$ | 33,696 | $ | 31,516 | $ | 19,268 | ||||||
|
Distributors
|
7,007 | 4,693 | 8,346 | |||||||||
|
Retailer and home shopping channels
|
9,761 | 5,992 | 4,845 | |||||||||
|
sub-total
|
50,464 | 42,201 | 32,459 | |||||||||
|
Physician Recurring
|
||||||||||||
|
XTRAC treatments
|
1,977 | 1,679 | - | |||||||||
|
Skin care
|
2,135 | 2,165 | - | |||||||||
|
Other
|
1,162 | 1,229 | - | |||||||||
|
sub-total
|
5,274 | 5,073 | - | |||||||||
|
Professional
|
3,168 | 2,999 | 1,388 | |||||||||
|
Total Revenues
|
$ | 58,906 | $ | 50,273 | $ | 33,847 | ||||||
|
PHOTOMEDEX, INC.
|
||||||||
|
CONDENSED CONSOLIDATED BALANCE SHEETS
|
||||||||
|
(UNAUDITED)
|
||||||||
|
Jun 30, 2012
|
Dec 31, 2011
|
|||||||
|
Assets
|
||||||||
|
Cash and cash equivalents
|
$ | 52,886 | $ | 16,549 | ||||
|
Accounts receivable, net
|
23,933 | 12,393 | ||||||
|
Inventories
|
21,113 | 19,208 | ||||||
|
Property and equipment, net
|
5,344 | 5,324 | ||||||
|
Other assets
|
100,149 | 92,089 | ||||||
|
Total Assets
|
$ | 203,425 | $ | 145,563 | ||||
|
Liabilities and Stockholders' Equity
|
||||||||
|
Accounts payable and accrued liabilities
|
$ | 34,265 | $ | 26,900 | ||||
|
Other current liabilities
|
3,602 | 1,948 | ||||||
|
Bank and lease notes payable
|
125 | 2,232 | ||||||
|
Other liabilities
|
3,441 | 2,405 | ||||||
|
Stockholders' equity
|
161,992 | 112,078 | ||||||
|
Total Liabilities and Stockholders' Equity
|
$ | 203,425 | $ | 145,563 | ||||
PHOTOMEDEX, INC.
CONDENSED STATEMENTS OF CASH FLOWS
(UNAUDITED)
|
For the Six Months ended June 30,
|
||||||||
|
2012
|
2011 | * | ||||||
|
CASH FLOWS FROM OPERATING ACTIVITIES:
|
||||||||
|
Net income
|
$ | 9,070 | $ | (1,960 | ) | |||
|
Adjustments to reconcile net income (loss) to
|
||||||||
|
net cash provided by operating activities--
|
||||||||
|
Depreciation and amortization
|
2,771 | 184 | ||||||
|
Provision for doubtful accounts
|
2,091 | 1,808 | ||||||
|
Stock based compensation
|
3,288 | 14,836 | ||||||
|
Deferred income taxes
|
(1,234 | ) | (6,105 | ) | ||||
|
Changes in assets and liabilities:
|
||||||||
|
(Increase) decrease in--
|
||||||||
|
Current assets
|
(23,717 | ) | (10,694 | ) | ||||
|
Current liabilities
|
10,076 | 16,538 | ||||||
|
Net cash provided by operating activities
|
2,345 | 14,607 | ||||||
|
CASH FLOWS FROM INVESTING ACTIVITIES:
|
||||||||
|
Lasers placed into service
|
(949 | ) | - | |||||
|
Purchases of PP&E, net
|
(218 | ) | (93 | ) | ||||
|
Other
|
(63 | ) | 8,428 | |||||
|
Net cash (used in) provided by investing activities
|
(1,230 | ) | 8,335 | |||||
|
CASH FLOWS FROM FINANCING ACTIVITIES:
|
||||||||
|
Proceeds from exercise of options/issuance of securities
|
37,653 | - | ||||||
|
Repayment of debt
|
(2,351 | ) | - | |||||
|
Net cash used in financing activities
|
35,302 | - | ||||||
|
EFFECT OF EXCHANGE RATE CHANGES ON CASH
|
(80 | ) | - | |||||
|
NET INCREASE IN CASH AND CASH EQUIVALENTS
|
36,337 | 22,942 | ||||||
|
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD
|
16,549 | 7,581 | ||||||
|
CASH AND CASH EQUIVALENTS, END OF PERIOD
|
$ | 52,886 | $ | 30,523 | ||||
*As a result of purchase accounting rules, the operating results of the pre-merged PhotoMedex for six- months ended June 30, 2011 are not included in the above condensed statements of cash flows for the period ended June 30, 2011.